Brief: Acorda Therapeutics Files For Voluntary Chapter 11 Protection
01/04/2024 23:37
April 1 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS AND MERZ ANNOUNCE SIGNING OF “STALKING
HORSE” ASSET PURCHASE AGREEMENT
* : ACORDA ENTERS INTO A RESTRUCTURING SUPPORT AGREEMENT
WITH OVER
90% OF SECURED CONVERTIBLE NOTEHOLDERS
* : PATIENT ACCESS TO INBRIJA(®) (LEVODOPA INHALATION
POWDER) AND
AMPYRA(® )(DALFAMPRIDINE) TO CONTINUE UNINTERRUPTED
* : ACORDA WILL CONTINUE OPERATIONS WHILE IT WORKS TO
COMPLETE
SALE PROCESS
* DEBTOR-IN-POSSESSION FINANCING AGREEMENT TO PROVIDE A TERM
LOAN
FACILITY IN AGGREGATE AMOUNT OF $20 MILLION IN NEW MONEY
* FILES FOR VOLUNTARY CHAPTER 11 PROTECTION TO FACILITATE
ORDERLY
SALE
* : ENTERED INTO AN ASSET PURCHASE AGREEMENT WITH MERZ
THERAPEUTICS TO PURCHASE ALL OF ASSETS OF ACORDA FOR $185
MILLION
Source text for Eikon: ID:nBw88fqda
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease